Medical devices and man-made materials have achieved major advances over recent decades. However, a new drumbeat is sounding in healthcare, as the steady growth in the use of biologics in medical procedures is gaining traction. Man-made materials will always have a place in the case of acute trauma, but biologics have the potential to take over as the most effective solution for degenerative conditions.
Join us for a rare gathering of international thought leaders sharing insights on crucial topics affecting our industries today. This comprehensive symposium is based on the definitive new publication “Biocompatibility and Performance of Medical Devices” assembled by ANSM expert Dr. Jean-Pierre Boutrand.
In the time it takes to read this piece, 30 Chinese men and women will die from heart disease. This staggering statistic means that as Asia continues to witness astonishing growth and development, Asians will increasingly wrestle with the disease. Heart disease is already the number one killer in China and India, and is fast on the rise throughout Southeast Asia, where the World Health Organization reports that cardiovascular diseases accounts for 27% of all deaths.
In 2008, a team of academic researchers shook up the connected medical device community by presenting a paper at an IEEE Symposium, which outlined a potential attack on implanted cardiac devices through the wireless interface. While this initially raised some concern, it was not until Jay Radcliffe demonstrated a potential attack through the wireless interface of a patient-worn insulin pump that awareness of medical device security issues “exploded,” prompting a U.S. Government Accountability Office inquiry into medical device security issues, and a media blitz that continues to this day.
What happens when a team of neurosurgeons, university professors, architects, students and engineers stands in front of an 8-foot-high theater screen with a 320-degree, immersive, 3-D view of their data? Cutting-edge science happens, and some are astonished by what is revealed.
A painstaking effort to create a biocompatible patch to heal infant hearts is paying off at Rice University and Texas Children's Hospital. The proof is in a petri dish in Jeffrey Jacot's lab, where a small slab of gelatinous material beats with the rhythm of a living heart.
Heart disease is a leading cause of death throughout the world. Doctors say that it is important to detect heart disease early before it becomes too serious. Now, researchers at the University of Missouri have found a way that they believe could help detect heart disease before it progresses too far as well as identify patients who are at risk for strokes.
Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has received 510(k) clearance from the FDA for the ONE Snare(TM) Endovascular Snare System.
Hearts previously rejected due to donors’ age or other risk factors can now be declared viable for transplantation using pharmacological stress echo, according to research presented at EUROECHO and other Imaging Modalities 2012. The study1 was presented by Dr Tonino Bombardini from Pisa, Italy.
A growing acceptance of drug-eluting stents as a more effective treatment for coronary heart disease, along with increasing awareness about coronary stents among patients, is expected to boost procedural volumes. As a result of these factors, the global market for coronary stents is estimated at over $5 billion...
Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy, today announced that it has acquired substantially all of the assets of Medigroup, Inc., a manufacturer of peritoneal dialysis catheters based in Illinois.
Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has entered into a stock purchase agreement to acquire Thomas Medical Products, Inc. ("Thomas Medical") from GE Healthcare in an all-cash transaction valued at approximately $167 million...
The recent staging of MEDICA 2012, International Trade Fair with Congress – World Forum for Medicine, and the concurrently held COMPAMED 2012, International Trade Fair – High tech solutions for medical technology, in Düsseldorf, Germany reflected the demand for medical technology and products with stable attendance figures: 130,600 visitors from 120 countries...
Chosen for nearly one out of every two endovascular abdominal aortic aneurysm repairs worldwide, the Endurant AAA stent graft system from Medtronic, Inc. continues to show robust results in mid-term follow-up, according to two-year clinical data presented at VEITHsymposium, which concluded yesterday in New York.
Active Signal Technologies Inc., Linthicum Heights, Md., a leading contract research firm specializing in electromechanical devices, has developed the first stethoscope that can detect heart/lung activity in high ambient noise (above 90 dBA) including combat casualty and civilian emergency medical environments.
For the first time, genetically engineered tomato plants produced a peptide that mimics the actions of good cholesterol when eaten, researchers reported at the American Heart Association's Scientific Sessions 2012. In the study, mice that ate the freeze-dried, ground tomatoes had less inflammation and reduced atherosclerosis (plaque build-up in the arteries).
Bypass surgery may be more expensive than drug-coated stents, but in the long run it's more cost effective for patients with diabetes because of superior long-term clinical outcomes, according to late-breaking clinical trial research presented at the American Heart Association's Scientific Sessions 2012.
An experimental device converted energy from a beating heart to provide enough electricity to power a pacemaker, in a study presented at the American Heart Association's Scientific Sessions 2012. The findings suggest that patients could power their pacemakers -- eliminating the need for replacements when batteries are spent.
Reinforcing its commitment to people with diabetes, Medtronic, Inc. (NYSE: MDT) is promoting its long-standing partnership with the International Diabetes Federation (IDF) through a new initiative surrounding “World Diabetes Day” on Nov. 14 that aims to engage interventional cardiologists worldwide in raising awareness of the connection between diabetes and coronary artery disease.
Medtronic Stent Successfully Treats Long Lesions and Small Vessels, Two Characteristics Typical of Patients with Diabetes, in Multiple StudiesOctober 23, 2012 11:44 am | by Medtronic | News | Comments
For the treatment of long lesions and small vessels –– two challenging characteristics of coronary artery disease commonly found in patients with diabetes –– the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) delivered successful clinical results, according to new data presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Vascular Solutions, Inc. today announced that it has launched the R-Band radial hemostasis compression device in the United States. Vascular Solutions is the exclusive distributor of the R-Band device in the U.S. under an agreement entered into with Lepu Medical Technology (Beijing) Co., Ltd., the developer and manufacturer of the device.
“Implantable devices can save lives and decrease mortality, they are not a luxury” said Professor Angelo Auricchio, President of the European Heart Rhythm Association (EHRA) of the ESC at the ICD for Life Summit which concluded in Belgrade, Serbia, today. “In the face of the impressive rise in cardiovascular related mortality in Central and Eastern Europe, we need to implement a structured approach...
Catheter balloons are an important device for a variety of cardiovascular treatments. However, their manufacture can be a complicated process that, if completed wrong, can lead to waste and excess costs. This article highlights a number of innovative technologies that are being offered to help balloon manufacturers ensure their products are defect-free the first time.
It’s not the journey, it’s the destination. In the case of interventional cardiovascular devices, both the journey and the destination are vital. These devices need to navigate the tortuous pathways of the vasculature in order to access and treat complex distal lesions. Getting there isn’t always easy.
When a manufacturer picks up a cardiovascular device, they literally hold someone’s life. There is no room for flaws in the quality of this product, or any other in the cardiovascular realm. These devices are shrinking, while becoming increasingly advanced—more intricate parts achieve more complex functions, within a surface area that leaves only enough space for perfection. So the case has never been greater for quality assurance. Conducting risk analysis through variation analysis software can satisfy it.